



저작자표시-비영리-동일조건변경허락 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.
- 이차적 저작물을 작성할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



동일조건변경허락. 귀하가 이 저작물을 개작, 변형 또는 가공했을 경우에는, 이 저작물과 동일한 이용허락조건하에서만 배포할 수 있습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

의학석사 학위논문

Magnetic Resonance Imaging Diagnosis of
Metastatic Lymph Nodes in a Rabbit Model:
Efficacy of PJY10, the New Ultrasmall
Superparamagnetic Iron Oxide Agent, with
Monodisperse Iron Oxide Core and
Multiple-Interaction Ligands

토끼 모델에서 MRI 를 사용한 전이림프절의 진단:
균질한 Iron Oxide Core 와 Multiple-Interaction
Ligand 로 구성된 새로운 Ultrasmall
Superparamagnetic Iron Oxide Agent 인 PJY10 의
효능

2014 년 2 월

서울대학교 대학원

의학과 영상의학 전공

유 노 을

A thesis of the Master's Degree

토끼 모델에서 MRI 를 사용한 전이림프절의 진단:
균질한 Iron Oxide Core 와 Multiple-Interaction
Ligand 로 구성된 새로운 Ultrasmall
Superparamagnetic Iron Oxide Agent 인 PJY10 의
효능

Magnetic Resonance Imaging Diagnosis of
Metastatic Lymph Nodes in a Rabbit Model:
Efficacy of PJY10, the New Ultrasmall
Superparamagnetic Iron Oxide Agent, with
Monodisperse Iron Oxide Core and
Multiple-Interaction Ligands

February 2014

The Department of Radiology,
Seoul National University
College of Medicine
Roh-Eul Yoo

Magnetic Resonance Imaging Diagnosis of
Metastatic Lymph Nodes in a Rabbit Model:
Efficacy of PJY10, the New Ultrasmall
Superparamagnetic Iron Oxide Agent, with
Monodisperse Iron Oxide Core and
Multiple–Interaction Ligands

by
Roh–Eul Yoo

A thesis submitted to the Department of Radiology
in partial fulfillment of the requirements for the
Master’s Degree in Radiology at Seoul National
University College of Medicine

February 2014

Approved by Thesis Committee:

Professor _____ Chairman

Professor _____ Vice chairman

Professor _____

Professor _____

Professor _____

ABSTRACT

Objectives: To evaluate the feasibility of detecting lymph node metastasis using the new ultrasmall superparamagnetic iron oxide particle, PJY10, in a rabbit model.

Materials and Methods: To make metastatic and benign lymph nodes, either VX2 carcinoma or fecal material suspension was inoculated into thighs of 56 rabbits three weeks or three days before magnetic resonance(MR) imaging, respectively. T2*-weighted 3T MR imaging was performed before and 24 hours after PJY10 injection(5.2 [n=15], 7.8 [n=17], and 10.4 [n=24] mg Fe/kg). MR images were correlated with pathologic results to calculate sensitivity and specificity. Quantitative analysis of the signal intensity(SI)-number of voxels_[low] (the fraction of the number of voxels with the normalized SI on the postcontrast image lower than that on the precontrast image) and mean SI ratio-was also performed for each lymph node, using Student's t-test, Pearson correlation and receiver operating characteristic(ROC) curve analyses.

Results: Sensitivities were 100% at all three dosages, whereas specificity increased with increasing dosage(89% at 10.4mg

Fe/kg). The benign nodes had a significantly higher number of voxels_[low] and a lower mean SI ratio than the metastatic nodes at the dosage of 10.4mg Fe/kg ($P < .001$). Az values were 0.905 for the number of voxels_[low] and 0.952 for the mean SI ratio. The number of voxels_[low] ($P = .019$) and the mean SI ratio ($P = .034$) had significant positive correlations with the histopathologic area ratio of metastatic foci in the metastatic nodes at 10.4mg Fe/kg.

Conclusion: PJY10 enabled clear demonstration of lymph node metastasis with high sensitivity and specificity at its optimal dosage of 10.4mg Fe/kg.

Keywords: PJY10, Ultrasmall superparamagnetic iron oxide (USPIO) particle, Lymph node metastasis, Magnetic resonance (MR) imaging, Rabbit

Student number: 2012–21701

CONTENTS

Abstract.....	i, ii
Contents.....	iii
List of tables and figures.....	iv, v
List of abbreviations.....	vi, vii
Introduction.....	1–3
Materials and Methods.....	4–14
Results.....	15–29
Discussion.....	30–37
Appendix.....	38–49
References.....	50–55
Abstract in Korean.....	56, 57

LIST OF TABLES AND FIGURES

Table 1. Number of All Removed Lymph Nodes Identified on Histopathologic Specimens.....	19
Table 2. Sensitivity and Specificity at Each PJY10 Dosage.....	20
Table 3. Quantitative Analysis: SI Difference between the Benign and Metastatic Lymph Nodes at Different PJY10 Dosages.....	21
Table 4. Quantitative Analysis: Az Values with Regard to Diagnosing Lymph Node Metastasis at Different PJY10 Dosage.....	22
Figure 1. Scatterplots demonstrating the results of the linear regression between the histopathologic area ratio ($Area_{ratio}$) and either the number of voxels _[low] (A) or the mean signal intensity (SI) ratio (B) at PJY10 dosage of 10.4 mg Fe/kg.....	23
Figure 2. A tumor model (New Zealand white rabbit weighing 2.5-3.0 kg) into which 10.4 mg Fe/kg of PJY10 was administered.....	24-25
Figure 3. A tumor model (New Zealand white rabbit weighing 2.5-3.0 kg) into which 10.4 mg Fe/kg of PJY10 was administered.....	26-27

Figure 4. An inflammation model (New Zealand white rabbit weighing 2.5–3.0kg) into which 10.4 mg Fe/kg of PJY10 was administered.....28–29

Appendix

Table S1. Pharmacokinetic Parameters of PJY10.....42

Figure S1. A normal rabbit (New Zealand white rabbit weighing 2.5–3.0kg) into which 10.4 mg Fe/kg of PJY10 was administered.....43

Figure S2. An electron microscopy image of PJY10 nanoparticle (magnification $\times 100,000$).....44

Figure S3. Plasma concentration–time curves of PJY10 in Sprague–Dawley (SD) male rats weighing 260–340g.....45

Figure S4. Ratio of the residual ^{59}Fe to the administered ^{59}Fe (ie, %ID) for a specific organ with respect to the time after PJY10 administration.....46–47

Figure S5. A tumor model (New Zealand white rabbit weighing 2.5–3.0 kg) into which 2.6 mg Fe/kg of MION–47 was administered.....48–49

LIST OF ABBREVIATIONS

Area under the curve (Az)

Computed tomography (CT)

Confidence intervals (CIs)

Field-emission Transmission Electron Microscope (FE-TEM)

Field of view (FOV)

¹⁸F-fluorodeoxyglucose (¹⁸F-FDG)

Food and Drug Administration (FDA)

Hematoxylin-eosin (H-E)

Hyperbranched polyethylenimine (bPEI)

Intravenous (IV)

Magnetic resonance (MR)

Methoxy poly(ethylene glycol) (mPEG)

Multiple-interaction ligand (MIL)

Poly(L-3,4-dihydroxyphenylalanine) (polyDOPA)

Poly(ethylene glycol) (PEG)

Receiver operating characteristic (ROC)

Regions of interest (ROIs)

Signal intensity (SI)

Sprague–Dawley (SD)

Terminal half–life ($T_{1/2}$)

Three–dimensional (3D)

Ultrasmall superparamagnetic iron oxide (USPIO)

INTRODUCTION

When a malignancy is diagnosed in a patient, decision on which path the patient is to take thereafter for the better treatment outcome heavily relies on the presence of the spread of primary malignancy to regional or distant lymph nodes. Albeit not as accurate as desired, cross-sectional imaging modalities such as computed tomography (CT) and magnetic resonance (MR) imaging have been the mainstay for assessing the local extent of primary malignancy as well as the regional lymph node involvement and distant metastases.¹ Traditionally, primary criterion for assessing the lymph node involvement has been the nodal size, with reported accuracies ranging from 63% to 75% for CT and 68% to 69% for MR imaging, respectively.¹ In an effort to improve the diagnostic accuracy, several studies have investigated various parameters -- specifically, nodal morphology, border, signal intensity (SI) characteristics, enhancement kinetics, apparent diffusion coefficient, and ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) and ¹⁸F-choline uptakes -- for their added values in diagnosing metastatic lymph nodes.²⁻¹⁰ Although some promising results have been reported with the use of the parameters, the inherent limitation in diagnosing

small metastatic or hyperplastic benign nodes has not been overcome, necessitating the development of a tissue-specific, highly sensitive and specific imaging technique to facilitate nodal characterization.¹

Ferumoxtran-10 (Combidex [Advanced Magnetics, Cambridge, MA, USA]; also known as Sinerem, AMI-7227, AMI-227, and BMS 180549) -- one of the most popular ultrasmall superparamagnetic iron oxide (USPIO) particles -- is a reticuloendothelial system-targeted MR contrast agent, specifically developed for MR lymphangiography.¹¹ Several studies on various body regions such as the head and neck, chest, abdomen, pelvis, and prostate demonstrated a significant improvement of the sensitivity and specificity in lymph node characterization after ferumoxtran-10 administration.¹² Furthermore, the contrast was reported to be clinically well-tolerated according to the comprehensive phase III efficacy and safety data, with the occurrence of only mild to moderate adverse events of short durations; therefore, it garnered substantial attention.¹³ Nevertheless, ferumoxtran-10 failed to receive the final Food and Drug Administration (FDA) approval as the FDA's Oncologic Drugs Advisory Committee concluded

that the data at the time were limited to a well-defined population of specific cancer types with questionable efficacy and safety in other types of tumors.

In pursuit of a new USPIO contrast agent with high efficacy and biocompatibility, we have synthesized PJY10 with multiple-interaction ligands inspired from a mussel adhesive protein.¹⁴ The purpose of this study was to evaluate the feasibility of detecting lymph node metastasis using the new USPIO particle in a rabbit model.

MATERIALS AND METHODS

This experiment was approved by the animal care committee at our institution.

Animal Preparation

The experiments were performed using 56 New Zealand white rabbits weighing 2.5– 3.0 kg. The animals were allowed food and water ad libitum.

To create an animal model of metastatic lymph nodes (ie, tumor model), the experimental VX2 carcinoma was prepared and a 1 mL of tumor suspension was inoculated intramuscularly into either side of the rabbit' s thighs (n = 32), following the previously reported method.¹⁵ As a counterpart of the tumor model, an animal model of benign lymph nodes (ie, inflammation model) was created by inoculating a 1 mL suspension of the rabbit' s fecal material into either side of the rabbit' s thighs (n = 24), with slight modifications to the previously described method.¹⁶

For the tumor model, MR imaging with a 3.0T scanner was performed three weeks after the tumor inoculation. On the

other hand, MR imaging was performed three days after the fecal material inoculation in the inflammation model.

In addition, MR imaging was also performed in three normal rabbits to evaluate the enhancement pattern in normal lymph nodes (see Supplemental Information and Figures S1(A) and S1(B), Supplemental Digital Content 1–3, which demonstrate PJY10 enhancement pattern in normal rabbits).

MR Contrast Material

PJY10, which is composed of a monodisperse iron oxide nanoparticle covered with a unique multiple–interaction ligand (MIL) (ie, poly(ethylene glycol) (PEG) derivatives), was prepared according to the previously described method¹⁴ with slight modifications and dispersed in a 0.9% sodium chloride solution. Structurally, MIL is a poly(L–3,4–dihydroxyphenylalanine) (polyDOPA) based ligand, consisting of methoxy poly(ethylene glycol) (mPEG) grafted cationic hyperbranched polyethylenimine (bPEI) and multi–initiated peptide domain of the polyDOPA.¹⁴ With respect to the particle size dispersity, the core size of the iron oxide nanoparticle was determined to be 13.0 ± 1.2 nm by a 200 kV Field–emission

Transmission Electron Microscope (FE-TEM) (JEM-2100F [HR]; JEOL Ltd., Tokyo, Japan) (see Supplemental Information and Figure S2, Supplemental Digital Content 1 and 4, which illustrate the particle size disparity). The particles were highly dispersible in aqueous conditions, and the hydrodynamic diameter was found to be 25–30 nm by means of dynamic light scattering (DLS, Nano ZS; Malvern Instrument Ltd., Malvern, England). The hydrodynamic diameter of PJY10 satisfied the recommended size criteria for lymphotropic superparamagnetic nanoparticle (ie, less than 30 nm).¹⁷ Furthermore, the optimal core size was determined from our preliminary study using nude mice. The T2 relaxivities of PJY10 measured using 1.5T (Signa HDXt or Signa Excite; GE Medical Systems, Milwaukee, Wis), 3.0T (TrioTim; Siemens, Erlangen, Germany), and 4.7T (Biospec 47/40; Bruker Medical Systems, Ettlingen, Germany) MR scanners were 123, 167, and 281 mM⁻¹s⁻¹, respectively. The concentration of iron in PJY10 was 20 mg Fe/mL. We also evaluated pharmacokinetic properties of PJY10 using rats and mice (see Supplemental Information, Table S1, Figures S3, S4(A), and S4(B), Supplemental Digital Content 1, 5–7, which demonstrate the

blood half-life of PJY10 in SPF Sprague-Dawley (SD) male rats and biodistribution of PJY10 in 6-week-old, male ICR mice).

MR Imaging Scanning

During MR image acquisition, the animals were sedated with an intramuscular injection of 50 mg of ketamine hydrochloride and 20 mg of xylazine hydrochloride per kilogram of body weight. In all 56 rabbits, MR imaging was performed with a 3.0T MR imager (TrioTim; Siemens, Erlangen, Germany) and a knee coil to improve the resolution of the scanner. In addition, the sigmoid colon and the rectum were filled with 80 mL of normal saline to minimize susceptibility artifacts due to the bowel gas.

At day one, after routine localization images, precontrast coronal T2*-weighted three-dimensional (3D) gradient-echo sequence was acquired. Based on the results from our preliminary study using mice, where the PJY10 concentration of 10.4 mg Fe/kg was shown to be the saturation dose, PJY10 was prepared in three different concentrations, 5.2, 7.8, and 10.4 mg Fe/kg. Subsequently, PJY10 was intravenously

administered via the ear veins of the rabbits. Postcontrast coronal T2*-weighted 3D gradient-echo sequence was acquired 24 hours after the contrast administration. The scans covered the entire region from the mid-abdomen to the upper thigh. The animals were imaged in the prone position. Imaging parameters including repetition time, echo time, number of signals acquired, and section thickness were modified to find the optimized values for accurate depiction of pelvic lymph nodes. Repetition time was varied from 51 to 400 msec, followed by echo time, which was varied from 15 to 24 msec. Section thickness was varied from 1 to 2 mm. Number of signals acquired was varied from two to four. Finally, two board-certified radiologists (S.H.C. and J.H.K. with seven and 15 years of experience in the interpretation of MR imaging studies) reviewed the images obtained using the various parameters and the optimal parameters were chosen as follows: repetition time (msec)/echo time (msec), 51/22; flip angle, 12° ; echo train length, 1; section thickness, 1 mm; field of view (FOV), 120 × 84 mm; matrix, 256 × 180; and number of signals acquired, 4.

Isolation of Lymph Nodes and Histopathologic Examination

After the acquisition of the postcontrast T2*-weighted MR images, the rabbits were sacrificed with a lethal dose (90 mg/kg) of intravenously administered sodium pentobarbital. The iliac and retroperitoneal lymph nodes were isolated by one author (R.Y.). The lymph nodes were dissected with the surrounding soft tissue at the iliac bifurcation in an en bloc fashion. Based on the MR image review prior to the lymph node dissection, the lymph nodes were labeled accordingly for the MR imaging-histopathologic correlation and fixed with 10% formalin. The lymph nodes were embedded in paraffin and then sectioned at 0.5-mm intervals. From each 0.5-mm section, a 5- μ m thick slide was prepared in the coronal plane for hematoxylin-eosin (H-E) staining and subsequently examined by a pathologist (J.K.W.) for the presence of metastasis.

For quantitative analysis, the long- and short-axis diameters of each lymph node were measured in the largest section, while the maximum diameters of metastatic foci were measured on representative slides. In some lymph nodes, the largest metastatic focus was not found in the largest section. For each metastatic lymph node, the following formula was used

to calculate the area ratio between the metastatic foci and the overall lymph node tissue:

$$\text{Area}_{\text{ratio}} = \frac{\sum(\text{long diameter} \times \text{short diameter})_{\text{metastatic foci}}}{(\text{long diameter} \times \text{short diameter})_{\text{overall lymph node tissue}}}$$

Image Analysis

Qualitative Analysis for Differentiation of the Benign and Malignant Lymph Nodes

The qualitative analysis was performed by two investigators (S.H.C. and J.H.K. with seven and 15 years of experience in the interpretation of MR imaging studies), who were blinded to the histopathologic information. The MR images were presented in random order by one author (R.Y.) and reviewed on a picture archiving and communication system workstation. A diagnosis of malignancy on the postcontrast T2*-weighted MR images was made by consensus, using the following criteria reported in previous studies^{13,18,19}: a lymph node with an overall high SI, an eccentric or central high SI with darkening along the peripheral rim was considered to be malignant. On the other hand, a node with an overall dark SI, an overall dark SI apart from the fatty hila, an overall dark SI with

tiny speckles of high SI, or a central low SI was considered to be nonmalignant.

Quantitative Analysis of the SI in Each Lymph Node

The SI of each lymph node was quantitatively analyzed by one author (R.Y.). Regions of interest (ROIs) that contained the entire lymph node were drawn in each section of the postcontrast T2*-weighted MR images, using Image-J software (National Institutes of Health, Bethesda, Md). The data acquired from each section were summated to derive voxel-by-voxel SI for the entire lymph node by using software developed in-house. At the same time, the overall mean SI of each lymph node on the precontrast MR image was measured by drawing the ROI along the margin of the lymph node on its representative section.

Given the earlier findings that the muscle tissue remains unchanged by the contrast agent^{20,21}, SI of the left thigh muscle was measured at a single ROI (5–7 mm² in size) on both the pre- and postcontrast MR images. Subsequently, the SI values of each voxel on the postcontrast MR image and the overall mean SI of the lymph node on the precontrast image were divided by the muscle SI to cancel the SI fluctuations related to

variations in technical parameters between the pre- and postcontrast images.

Finally, the fraction of the number of voxels with the normalized SI on the postcontrast image lower than that on the precontrast image (ie, number of voxels_[low]) was determined. Additionally, the mean SI ratio between the pre- and postcontrast images was calculated using the following formula:
$$\text{SI ratio} = (\text{SI lymph node}_{[\text{post-USPIO}]} / \text{SI muscle}_{[\text{post-USPIO}]}) / (\text{SI lymph node}_{[\text{pre-USPIO}]} / \text{SI muscle}_{[\text{pre-USPIO}]}).$$

Statistical Analysis

Statistical analyses were performed by using commercially available software (MedCalc, version 8.0.0.1; MedCalc software, Mariakerke, Belgium). The data for each parameter was assessed for normality with the Kolmogorov-Smirnov test. In all tests, *P* values less than .05 were considered statistically significant.

Qualitative Analysis for Differentiation of the Benign and Metastatic Lymph Nodes

Sensitivity and specificity for differentiation of the benign and metastatic lymph nodes were calculated for each

PJY10 dosage (5.2, 7.8, 10.4 mg Fe/kg). Data clustering (ie, more than one lesion per rabbit) was accounted for with the method of Rao and Scott.²²

Quantitative Analysis of the SI in Each Lymph Node

For each contrast dosage, the unpaired Student t test was used to assess whether the number of voxels_[low] and the mean SI ratio of the benign lymph nodes differed significantly from those of the metastatic lymph nodes.

The receiver operating characteristic (ROC) curve analysis was performed to estimate the area under the curve (Az) based on the number of voxels_[low] and the mean SI ratio.

As for the metastatic lymph nodes, Pearson correlation analysis was performed to measure the significance of the association between the histopathologic area ratio (Area_{ratio}) and either the number of voxels_[low] or the mean SI ratio for each contrast dosage. Regression analysis of the data was performed using the general linear model.

Diagnostic Yields at the Optimal (Lowest Effective) Dosage

Regarding the optimal (lowest effective) contrast dosage, ROC curves were constructed for both the number of voxels_[low] and the mean SI ratio to determine cutoff levels that

provided a balance between sensitivity and specificity for the diagnosis of lymph node metastasis. The sensitivity and specificity at the optimal cutoff levels as well as the Az values were calculated, along with 95% confidence intervals (CIs).

Sensitivity and Specificity for Detection of Lymph Node Metastasis: Comparison of PJY10 with MION-47

Sensitivity and specificity for detection of lymph node metastasis were compared between the two groups (PJY10 group [10.4 mg Fe/kg] vs. MION-47 group [2.6 mg Fe/kg]) (see Supplemental Information, Supplemental Digital Content 1, which includes statistical data for comparison of PJY10 and MION-47; see Figures S5(A)–(C), Supplemental Digital Content 8–10, which demonstrates a true-positive case of the metastatic lymph nodes in MION-47 group).

RESULTS

Histopathology

The numbers of benign and metastatic lymph nodes isolated from the rabbit models (ie, tumor and inflammation models) are summarized for each PJY10 dosage in Table 1. 10.4 mg Fe/kg of PJY10 was administered to 24 rabbits (12 tumor models and 12 inflammation models), whereas 7.8 mg Fe/kg of PJY10 was administered to 17 rabbits (11 tumor models and 6 inflammation models). 5.2 mg Fe/kg of PJY10 was administered to 15 rabbits (9 tumor models and 6 inflammation models). The mean long- and short-axis diameters of the benign lymph nodes were 8.0 ± 3.2 and 3.6 ± 1.4 mm. In comparison, the mean long- and short-axis diameters of the metastatic lymph nodes were 10.6 ± 3.8 and 6.6 ± 2.4 mm. Moreover, the mean long- and short-axis diameters of the metastatic foci were 2.5 ± 2.8 and 1.7 ± 1.9 mm.

MR Image Analysis

Qualitative Analysis for Differentiation of the Benign and Malignant Lymph Nodes

Sensitivity and specificity at each PJY10 dosage are provided in Table 2. The sensitivity was 100% (20 of 20, 17 of 17, and 18 of 18 in 5.2, 7.8, and 10.4 mg Fe/kg, respectively) in all three dosages, whereas the specificity increased with increasing dosage, with the dosage of 10.4 mg Fe/kg having the highest specificity of 89% (47 of 53).

Quantitative Analysis of the SI in Each Lymph Node

The mean SI ratio in the benign lymph nodes was significantly lower than that in the malignant lymph nodes at the dosages of 7.8 and 10.4 mg Fe/kg ($P < .001$ for both). Accordingly, the number of voxels_[low] was significantly higher for the benign lymph nodes than for the metastatic lymph nodes at the dosage of 10.4 mg Fe/kg ($P < .001$). The benign lymph nodes had a higher number of voxels_[low] than the metastatic lymph nodes at the dosage of 7.8 mg Fe/kg, although the level did not achieve statistical significance ($P = .077$) (Table 3).

With regard to diagnosing lymph node metastasis, the Az values from the ROC analysis tended to increase for both the number of voxels_[low] and the mean SI ratio, with increasing PJY10 dosage (Table 4).

Both the number of voxels_[low] and the mean SI ratio had statistically significant correlations with the histopathologic area ratio (Area_{ratio}) only at the dosage of 10.4 mg Fe/kg ($r = -0.142, P = .552$; $r = 0.233, P = .322$ for 5.2 mg Fe/kg; $r = -0.034, P = .897$; $r = 0.114, P = .664$ for 7.8 mg Fe/kg; $r = -0.545, P = .019$; $r = 0.502, P = .034$ for 10.4 mg Fe/kg) (Fig. 1).

Diagnostic Yields at the Optimal (Lowest Effective) Dosage of 10.4 mg Fe/kg

According to the results presented in Figure 1 and Tables 2–4, the concentration of 10.4 mg Fe/kg was selected as the optimal (lowest effective) dosage of PJY10 for diagnosing lymph node metastasis. Representative cases of the metastatic and benign lymph nodes at the dosage of 10.4 mg Fe/kg are shown in Figures 2–4.

At the dosage of 10.4 mg Fe/kg, the cutoff values that provided a balance between sensitivity and specificity for the diagnosis of lymph node metastasis were 0.992 for the number of voxels_[low] and 0.533 for the mean SI ratio. The corresponding sensitivities and specificities at the cutoff values were 89% (95% CI: 65, 99) and 81% (95% CI: 68, 91) for the

number of voxels_[low] and 100% (95% CI: 82, 100) and 81% (95% CI: 68, 91) for the mean SI ratio. The Az values were 0.905 (95% CI: 0.812, 0.962) and 0.952 (95% CI: 0.873, 0.988) for the number of voxels_[low] and the mean SI ratio, respectively.

	PJY10 dosage (mg Fe/kg)		
	5.2	7.8	10.4
Number of rabbits	15	17	24
Number of benign nodes	45	51	53
Number of metastatic nodes	20	17	18

TABLE 1. Number of All Removed Lymph Nodes Identified on Histopathologic Specimens

	PJY10 dosage (mg Fe/kg)		
	5.2	7.8	10.4
Sensitivity (%)	100 (20 of	100 (17 of	100 (18 of
[95% CI]	20)	17)	18)
	[74, 100]	[77, 100]	[74, 100]
Specificity (%)	62 (28 of 45)	71 (36 of 51)	89 (47 of 53)
[95% CI]	[45, 79]	[58, 83]	[78, 99]

TABLE 2. Sensitivity and Specificity at Each PJY10 Dosage

Data clustering (ie, more than one lesion per rabbit) was accounted for with the method of Rao and Scott.²² Data in parentheses are the raw data used to calculate the percentages, and data in square brackets are 95% confidence intervals (CI) expressed as percentages.

	PJY10 dosage (mg Fe/kg)		
	5.2	7.8	10.4
Number of voxels _[low] *			
Benign nodes	0.916 (n = 45)	0.931 (n = 51)	0.989 (n = 53)
Metastatic nodes	0.869 (n = 20)	0.823 (n = 17)	0.831 (n = 18)
P value	.240	.077	< .001
Mean SI ratio †			
Benign nodes	0.619 (n = 45)	0.560 (n = 51)	0.407 (n = 53)
Metastatic nodes	0.716 (n = 20)	0.777 (n = 17)	0.749 (n = 18)
P value	.070	< .001	< .001

TABLE 3. Quantitative Analysis: SI Difference between the Benign and Metastatic Lymph Nodes at Different PJY10 Dosages


Data in parentheses are the number of lymph nodes. *The number of voxels_[low] represents the fraction of the number of voxels with the normalized SI on the postcontrast image lower than that on the precontrast image. † The mean signal intensity (SI) ratio between pre- and postcontrast images is calculated using the following formula: $SI\ ratio = (SI\ lymph\ node_{[post-USPIO]} / SI\ muscle_{[post-USPIO]}) / (SI\ lymph\ node_{[pre-USPIO]} / SI\ muscle_{[pre-USPIO]})$.

	PJY10 dosage (mgFe/kg)		
	5.2	7.8	10.4
Number of voxels _[low]	0.647	0.779	0.905
[95% CI] *	[0.518, 0.761]	[0.661, 0.870]	[0.812, 0.962]
Mean SI ratio	0.627	0.785	0.952
[95% CI] †	[0.498, 0.744]	[0.669, 0.876]	[0.873, 0.988]

TABLE 4. Quantitative Analysis: Az Values with Regard to Diagnosing Lymph Node Metastasis at Different PJY10 Dosage

Data in square brackets are 95% confidence intervals (CI) expressed as percentages. * The number of voxels_[low] represents the fraction of the number of voxels with the normalized SI on the postcontrast image lower than that on the precontrast image. † The mean signal intensity (SI) ratio between pre- and postcontrast images is calculated using the following formula: $SI\ ratio = (SI\ lymph\ node_{[post-USPIO]} / SI\ muscle_{[post-USPIO]}) / (SI\ lymph\ node_{[pre-USPIO]} / SI\ muscle_{[pre-USPIO]})$.

(A)



(B)




FIGURE 1. Scatterplots demonstrating the results of the linear regression between the histopathologic area ratio (Area_{ratio}) and either the number of voxels_[low] (A) or the mean signal intensity (SI) ratio (B) at PJY10 dosage of 10.4 mg Fe/kg. The best-fit line (ie, the graph of the linear regression equation) is shown as a solid line. The curves above and below the best-fit line represent the upper and lower bounds of the 95% confidence interval (CI).

(A)



(B)



(C)



FIGURE 2. A tumor model (New Zealand white rabbit weighing 2.5–3.0 kg) into which 10.4 mg Fe/kg of PJY10 was administered.

(A,B) An ovoid right common iliac lymph node with a short-axis diameter of 0.3 cm shows a focal signal drop at its superior

aspect (arrow) on the postcontrast coronal T2*-weighted MR image (B), compared with the precontrast image (A). (C) The hematoxylin-eosin (H-E) stained pathology specimen at low-power field (magnification $\times 40$) well-demonstrates a metastatic focus (arrowheads) at the inferior aspect of the lymph node, corresponding to the portion with no signal drop on the postcontrast MR image (B).

(A)

(B)



(C)






FIGURE 3: A tumor model (New Zealand white rabbit weighing 2.5– 3.0 kg) into which 10.4 mg Fe/kg of PJY10 was administered. (A, B) Another enlarged lymph node (arrow) at

the iliac bifurcation remains unchanged on the postcontrast coronal T2*-weighted MR image (B), compared with the precontrast image (A). (Some susceptibility artifact due to adjacent bowel gas is present on the precontrast image.) (C) Multiple metastatic foci (arrowheads) were confirmed on the hematoxylin-eosin (H-E) stained pathology specimen (magnification $\times 40$).

(A)



(B)



(C)




FIGURE 4: An inflammation model (New Zealand white rabbit weighing 2.5– 3.0kg) into which 10.4 mg Fe/kg of PJY10 was administered. (A, B) The pre- (A) and postcontrast (B) coronal T2*-weighted MR images demonstrate a central

darkening of an enlarged lymph node (arrow) in the right common iliac area. (C) An electron microscopy image of the lymph node confirmed the presence of contrast particles (arrowheads) within the cytoplasmic organelle of the lymph node macrophage (magnification $\times 20,000$).

DISCUSSION

The present study evaluated the feasibility of detecting lymph node metastasis in a rabbit model using PJY10, a new USPIO contrast agent with a monodisperse iron oxide core and multiple–interaction ligands. The use of the contrast dosage of 10.4 mg Fe/kg yielded the sensitivity of 100% and specificity of 89% in the subjective analysis based on the previously reported criteria.^{13, 18, 19} Moreover, the number of voxels_[low] and the mean SI ratio were used to measure the SI difference between the benign and metastatic lymph nodes, and the benign lymph nodes were shown to have a significantly higher number of voxels_[low] and a lower mean SI ratio compared with the metastatic lymph nodes. At the optimal (lowest effective) dosage of 10.4 mg Fe/kg, the Az values were 0.905 for the number of voxels_[low] and 0.952 for the mean SI ratio. The number of voxels_[low] and the mean SI ratio also had significant positive correlations with the histopathologic area ratio between the metastatic foci and the overall lymph node tissue.

Ever since the introduction of contrast–enhanced MR lymphangiography, a number of diverse compounds have been rigorously developed for varying routes of administration, ie,

direct or endolymphatic, indirect or interstitial, and intravenous (IV) injection.²³ Compared with the interstitial route of administration, the IV injection is advantageous in that it yields a higher reproducibility in the imaging performance and allows evaluation of distant as well as regional lymph nodes with a single injection.²³

USPIO particles were the first contrast media used for the IV MR lymphangiography. After IV administration, these compounds are transported to the lymph nodes by the lymphatic vessels and phagocytosed by functional macrophages in the nonmetastatic lymph node tissue.^{23,24} Once accumulated in the functional macrophages, the T2* effect of the iron oxide particles causes the signal drop of the nonmetastatic lymph nodes on the USPIO-enhanced MR image. In contrast, the SI of the metastatic lymph nodes deprived of the functional macrophages remains unchanged.²³ Thus, USPIO-enhanced MR imaging is believed to enable identification of metastatic areas within the lymph nodes independently of the lymph node size.²⁵

Two fundamental prerequisites for the successful biomedical use of the USPIO particles have been reported: 1) strong T2 relaxivity, which leads to a marked decrease in SI

(negative enhancement) on the postcontrast image and 2) colloidal stability or biocompatibility in harsh biological environments.^{14, 26} Ferumoxtran-10 (Combidex; Advanced Magnetix, Cambridge, MA, USA), most widely evaluated first-generation USPIO particle, is 20– 50 nm (mean 35 nm) in size, and composed of an iron oxide crystalline core of 4.3– 6.0 nm covered by low-molecular-weight dextran. The T1 and T2 relaxivities of the compound were found to be 23 mM⁻¹s⁻¹ and 53 mM⁻¹s⁻¹ (20 MHz, 39 ° C), respectively, in 0.5% agar.²⁷ A meta-analysis of the diagnostic precision of ferumoxtran-10-enhanced MR imaging for lymph node metastasis has shown an overall sensitivity of 0.88 and specificity of 0.96.¹²

The pursuit of higher T2 relaxivity and biocompatibility led to the development of the new USPIO contrast agent, PJY10. First, PJY10 was found to have a T2 relaxivity of 281 mM⁻¹s⁻¹ at 4.7T, which was three times higher than that of Combidex (94 mM⁻¹s⁻¹) under the same conditions. T2 relaxivities of PJY10 measured at 1.5 and 3.0T (ie, 123 and 167 mM⁻¹s⁻¹, respectively) were also higher than those of Combidex reported in the previous literature (ie, 100 and 128 mM⁻¹s⁻¹, respectively).²⁶ The higher T2 relaxivity of PJY10 can be

attributed to its larger and more uniform core (13 ± 2 nm, compared with 4.3– 6.0 nm in Combidex), along with its higher crystallinity, as T2 relaxivity (R_2) of the nanoparticles is defined by

$$R_2 = \frac{(\frac{64\pi}{135000})\gamma^2 N_A M \mu_c^2}{rD}$$

where N_A is Avogadro's number, M is the particle molarity (moles L^{-1}), μ_c is the magnetic moment of the nanoparticle, which is proportional to its volume, r is the effective radius of the nanoparticle, and D is the diffusion coefficient of water molecules. In order to obtain the large, uniform core and high crystallinity, thermal decomposition method was employed instead of coprecipitation method which has been used for the conventional T2 agents.^{28–30} Overall size of PJY10, however, was designed to be small enough as 25–30 nm to ensure a longer blood half-life, based on the fact that the particle size is the main factor that has a major influence on its blood half-life and biodistribution. Small nanoparticles are known to have a longer plasma-circulation time due to their slow excretion by the liver, thus suggesting the recommended size criteria for

lymphotropic superparamagnetic nanoparticles to be less than 30 nm.³¹

Second, a unique multiple–interaction ligand (MIL), inspired from a mussel adhesive protein, was developed to achieve higher biocompatibility.¹⁴ Each component of the MIL contributes to the overall biocompatibility by providing various binding modes. First, the polyDOPA domain and the primary amine end groups of the MIL enable the simultaneous binding of multiple catechols and amines onto the surface of the hydrophobic nanoparticles.³² Second, the amphiphilic hyperbranched block copolymer structure with both hydrophobic polyDOPA and hydrophilic PEG groups generates micelles encapsulating the nanoparticles. Third, the positively charged bPEI moiety can interact electrostatically with negatively charged metals and metal oxides of the nanoparticles.¹⁴ Enhanced stability via the various binding modes was reflected in the results of our in vitro stability test, which proved that the new USPIO particle was highly stable at various salt concentrations, pH levels, temperatures, and in a high iron concentration of 15 mg Fe/mL.¹⁴

Our new USPIO contrast agent with the specific design for the optimal T2 relaxivity and biocompatibility showed a high sensitivity and specificity (100% and 89%, respectively) for diagnosing lymph node metastasis at the dosage of 10.4 mg Fe/kg. Our preliminary study comparing PJY10 with MION-47 has shown a higher sensitivity in the PJY10 group but it did not reach the statistical significance ($P = .064$).

Although the most commonly used diagnostic guideline for the interpretation of USPIO-enhanced MR images is based on the patterns of contrast enhancement, such practice has a major drawback in that it inevitably involves a certain level of subjectivity, as noted by Islam and Harisinghani.¹ Instead, Lahaye et al used the estimation of percentage of high SI within the node as a measure of lymph node metastasis in primary rectal cancer and found a cut-off value of 30% to be highly predictive for an involved node, with a sensitivity of 93% and a specificity of 96%.³³ Similarly, a previous study using MION-47 has shown that the mean SI ratio between pre- and postcontrast images was a useful parameter in the differential diagnosis of the benign and metastatic lymph nodes, with a cut-off value of 0.533 resulting in a sensitivity of 93% and a

specificity of 83%.³⁴ In the present study, we evaluated the mean SI ratio as a complement to our qualitative analysis based on the previously reported diagnostic guideline. The metastatic lymph nodes were shown to have a significantly higher mean SI ratio than the benign lymph nodes ($P < .001$), with a cut-off value of 0.533 at the contrast dosage of 10.4 mg Fe/kg yielding a sensitivity of 100% and a specificity of 81%. Furthermore, our study demonstrated that the mean SI ratio had a significant positive correlation with the histopathologic area ratio between the metastatic foci and the overall lymph node tissue in the metastatic lymph nodes, implying that the mean SI ratio may be a useful imaging biomarker for the tumor burden.

Our study had a few limitations. First, T1- and T2-weighted images, known to enhance the visualization of anatomy including the fatty hila, were not performed in this study.¹ Nonetheless, pre- and postcontrast T2*-weighted gradient-echo sequences have been shown to be the key sequences for displaying USPIO particle uptakes in lymph nodes and the imaging parameters in our study were optimized in a way that the acquisition of the T2*-weighted 3D gradient-echo sequences alone was adequate for delineation of the relevant anatomy. Second, the

need for two MR imaging scans 24 hours apart could be a limitation in terms of time and costs, as in the case of ferumoxtran-10. However, Harisinghani et al found no significant difference in the diagnostic precision between paired MR imaging (unenhanced MR imaging followed by ferumoxtran-10-enhanced MR imaging) and postcontrast MR imaging alone for an experienced reviewer.³⁵ Further study is warranted to assess whether the PJY10-enhanced MR imaging alone may as well be sufficient to diagnose lymph node metastasis.

In conclusion, our experimental study with a rabbit model has demonstrated that PJY10, the new USPIO contrast agent with high T2 relaxivity and biocompatibility, may be a promising agent in the oncologic field by enabling clear demonstration of lymph node metastasis with high sensitivity and specificity at its optimal (lowest effective) dosage of 10.4 mg Fe/kg.

APPENDIX

PJY10 for Detection of Lymph Nodes in Normal Rabbits:

- An experimental study with normal rabbits has demonstrated that the normal rabbits often have small lymph nodes that are beyond the spatial resolution of the conventional 3T MR. In cases with discernible lymph nodes, patterns of contrast enhancement suggestive of the benignity, such as a central low signal intensity, were evident as shown in Figure S1.

Particle Size Dispersity:

- Core sizes (diameter; nm) of 200 PJY10 particles were measured using a 200 kV Field-emission Transmission Electron Microscope (FE-TEM) (JEM-2100F [HR]; JEOL Ltd., Tokyo, Japan) (magnification $\times 100,000$) to assess the particle size dispersity (Fig S2).

Pharmacokinetic Properties of PJY10:

1) Blood half-life:

- 36 SPF Sprague-Dawley (SD) male rats weighing 260-340g were divided into three groups (ie, T1-3; 12 each) and PJY10 was intravenously administered via their tail veins as follows:

5.2 mg Fe/kg to T1; 10.4 mg Fe/kg to T2; and 20.8 mg Fe/kg to T3. The concentrations of PJY10 were derived from the T2 relaxation times of the plasma samples, which were measured at a 4.7T MR imager (Biospec 47/40; Bruker Medical Systems, Ettlingen, Germany). Additionally, pharmacokinetic parameters were derived from plasma concentration–time curves using WinNonlin™ (Ver. 5.2.1, Pharsight, Co., USA) software. Results are shown in Figure S3 and Table 1. Terminal half–life ($T_{1/2}$) was 2.0–2.1 h in all three concentrations. Plasma concentration decreased linearly to less than 0.5 $\mu\text{g Fe/mL}$, limit of detection, 12–24 hours after the administration. No lethal adverse reaction occurred during the experiment.

2) Biodistribution:

– Biodistribution of PJY10 was studied using 36 6–week–old, male ICR mice. Prior to the administration, PJY10 nanoparticles were tagged with ^{59}Fe by adding a small amount of $^{59}\text{FeCl}_3$ in the first step of PJY10 synthesis. The ^{59}Fe –tagged PJY10 nanoparticles (10.4 mg Fe/kg) were intravenously administered via their tail veins. At 2/5/10/30 minutes, 1/6 hours, 1/3/10/30/91/182 days following the administration, blood sampling and organ harvesting (muscle, bone, fat, heart, liver,

spleen, lungs, kidneys, intestines, pancreas, stomach, inguinal/axillary/brachial lymph nodes) were performed. Three mice were sacrificed at each time point. Ratio of the residual ^{59}Fe to the administered ^{59}Fe (ie, %ID) was measured with a gamma counter and subsequently %ID per gram of the organ (%ID/g) as well as %ID per organ as a whole (%ID/organ) were calculated for each organ. Changes in %ID/organ and %ID/g with respect to time are demonstrated in Figure S4. Major ^{59}Fe uptakes (%ID/g) were observed in the lymph nodes, blood, liver, and spleen. Specifically, %ID/g of the lymph nodes showed an overall tendency to increase in the first three to ten days and decrease thereafter.

Sensitivity and Specificity for Detection of Lymph Node Metastasis: Comparison of PJY10 with MION-47

- Sensitivity and specificity for detection of lymph node metastasis were compared between the two groups (PJY10 group [10.4 mg Fe/kg] vs. MION-47 group [2.6 mg Fe/kg]) using Fischer exact test. Sensitivity of the PJY10 group was higher than that of the MION-47 group; however, it did not reach the statistical significance (100% [18 of 18] vs. 77% [10

of 13], $P = .064$). There was no significant difference in the specificity of the two groups (89% [47 of 53] vs. 75% [18 of 24], $P = .175$). Figure S5 represents a true-positive case of the metastatic lymph nodes.

For more accurate comparison, however, it would be more appropriate to use paired data by assigning the same individuals to both groups. Nonetheless, the two different USPIO particles could not be administered to the same individual rabbits considering their relatively long clearance times.

Group	Dose	Gen der	K_{el}	$T_{1/2}$	AUC_{inf}	T_{max}	C_{max}	CL
	(mg Fe/ kg)		(1/h)	(h)	(μ g Fe·h/ mL)	(h)	(μ g Fe/ mL)	(mL/ h/kg)
T1	5.2	Male	0.34	2.0	33.9	0.03	39.9	153.
						3		6
T2	10.4	Male	0.33	2.1	89.7	0.03	73.0	115.
						3		9
T3	20.8	Male	0.34	2.1	290.9	0.03	158.	71.5
						3	2	

TABLE S1. Pharmacokinetic Parameters of PJY10. Data are derived from plasma concentration–time curves. K_{el} = apparent terminal elimination rate constant, $T_{1/2}$ = terminal half–life, AUC_{inf} = area under the plasma concentration–time curve from 0 h to infinity, with an extrapolation to the time infinity, T_{max} = time at which C_{max} is observed, C_{max} = maximum observed peak serum concentration, CL = total clearance.

(A)

(B)




FIGURE S1: A normal rabbit (New Zealand white rabbit weighing 2.5– 3.0kg) into which 10.4 mg Fe/kg of PJY10 was administered. (A, B) The pre- (A) and postcontrast (B) coronal T2*-weighted MR images demonstrate an overall darkening of a small lymph node (arrow) in the right common iliac area after PJY10 administration.




FIGURE S2: An electron microscopy image of PJY10 nanoparticle (magnification $\times 100,000$).





FIGURE S3: Plasma concentration–time curves of PJY10 in Sprague–Dawley (SD) male rats weighing 260–340g.

(A)



(B)





FIGURE S4: Ratio of the residual ^{59}Fe to the administered ^{59}Fe (ie, %ID) for a specific organ with respect to the time after

PJY10 administration. (A) %ID per organ as a whole (%ID/organ) according to the time. (B) %ID per gram of the organ (%ID/g) according to the time.

(A)

(B)



(C)




FIGURE S5: A tumor model (New Zealand white rabbit weighing 2.5–3.0 kg) into which 2.6 mg Fe/kg of MION-47 was administered. (A, B) An enlarged lymph node at the iliac

bifurcation (arrows) showed no discernible signal drop on the postcontrast coronal T2*-weighted MR image (B), compared with the precontrast image (A). (C) The hematoxylin-eosin (H-E) stained pathology specimen revealed multiple large metastatic foci (arrowheads) (magnification $\times 40$).

REFERENCES

1. Islam T, Harisinghani MG. Overview of nanoparticle use in cancer imaging. *Cancer biomark.* 2009;5:61–67.
2. Kitajima K, Murphy RC, Nathan MA. Choline PET/CT for imaging prostate cancer: an update. *Ann Nucl Med.* 2013 Apr 30. [Epub ahead of print].
3. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. *Radiology.* 2003;229:526–533.
4. Brown G, Richards CJ, Bourne MW, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. *Radiology.* 2003;227:371–377.
5. Choi EK, Kim JK, Choi HJ, et al. Node-by-node correlation between MR and PET/CT in patients with uterine cervical cancer: diffusion-weighted imaging versus size-based criteria on T2WI. *Eur Radiol.* 2009;19:2024–2032.
6. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal

staging in the 1990s--meta-analytic comparison of PET and CT. *Radiology*. 1999;213:530-536.

7. Fischbein NJ, Noworolski SM, Henry RG, et al. Assessment of metastatic cervical adenopathy using dynamic contrast-enhanced MR imaging. *AJNR Am J Neuroradiol*. 2003;24:301-311.

8. Kim JH, Beets GL, Kim MJ, et al. High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? *Eur J Radiol*. 2004;52:78-83.

9. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. *N Engl J Med*. 2000;343:254-261.

10. Vesselle H, Pugsley JM, Vallieres E, et al. The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2002;124:511-519.

11. Harisinghani MG, Dixon WT, Saksena MA, et al. MR lymphangiography: imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10. *Radiographics*. 2004;24:867-878.

12. Will O, Purkayastha S, Chan C, et al. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. *Lancet Oncol.* 2006;7:52–60.
13. Anzai Y, Piccoli CW, Outwater EK, et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. *Radiology.* 2003;228:777–788.
14. Ling D, Park W, Park YI, et al. Multiple-interaction ligands inspired by mussel adhesive protein: synthesis of highly stable and biocompatible nanoparticles. *Angew Chem Int Ed Engl.* 2011;50:11360–11365.
15. Dunne AA, Mandic R, Ramaswamy A, et al. Lymphogenic metastatic spread of auricular VX2 carcinoma in New Zealand white rabbits. *Anticancer Res.* 2002;22:3273–3279.
16. Wolf GL, Gazelle GS, McIntire GL, et al. Percutaneous computed tomography lymphography in the rabbit by subcutaneously injected nanoparticulates. *Acad Radiol* 1994;1:352–357.
17. Lind K, Kresse M, Debus NP, et al. A novel formulation for superparamagnetic iron oxide (SPIO) particles enhancing

MR lymphography: comparison of physicochemical properties and the in vivo behaviour. *J Drug Target*. 2002;10:221–230.

18. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph–node metastases in prostate cancer. *N Engl J Med*. 2003;348:2491–2499.

19. Koh DM, Brown G, Temple L, et al. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings—initial observations. *Radiology*. 2004;231:91–99.

20. Hauger O, Delalande C, Deminiere C, et al. Nephrotoxic nephritis and obstructive nephropathy: evaluation with MR imaging enhanced with ultrasmall superparamagnetic iron oxide—preliminary findings in a rat model. *Radiology*. 2000;217:819–826.

21. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. *AJR Am J Roentgenol*. 1989;152:167–173.

22. Rao JN, Scott AJ. A simple method for the analysis of clustered binary data. *Biometrics*. 1992;48:577–585.

23. Misselwitz B. MR contrast agents in lymph node imaging. *Eur J Radiol.* 2006;58:375–382.
24. Torabi M, Aquino SL, Harisinghani MG. Current concepts in lymph node imaging. *J Nucl Med.* 2004;45:1509–1518.
25. Narayanan P, Iyngkaran T, Sohaib SA, et al. Pearls and pitfalls of MR lymphography in gynecologic malignancy. *Radiographics.* 2009;29(4):1057–1069.
26. Simon GH, Bauer J, Saborovski O, et al. T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning. *Eur Radiol.* 2006;16:738–745.
27. Bellin MF, Lebleu L, Meric JB. Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography. *Abdom Imaging.* 2003;28:155–163.
28. Lee NH, Hyeon TH. Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents. *Chem Soc Rev.* 2012;41:2575–2589.
29. Bellin MF, Beigelman C, Precetti-Morel S. Iron oxide-enhanced MR lymphography: initial experience. *Eur J Radiol.* 2000;34:257–264.

30. Jun YW, Huh YM, Choi JS, et al. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. *Am Chem Soc.* 2005;127:5732–5733.
31. Na HB, Song IC, Hyeon TH. Inorganic nanoparticles for MRI contrast agents. *Adv. Mater.* 2009;21:2133–2148.
32. Duan H, Nie S. Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings. *J Am Chem Soc.* 2007;129:3333–3338.
33. Lahaye MJ, Engelen SM, Kessels AG, et al. USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. *Radiology.* 2008;246:804–811.
34. Choi SH, Kim KH, Moon WK, et al. Comparison of lymph node metastases assessment with the use of USPIO-enhanced MR imaging at 1.5 T versus 3.0 T in a rabbit model. *J Magn Reson Imaging.* 2010;31:134–141.
35. Harisinghani MG, Saksena MA, Hahn PF, et al. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? *AJR Am J Roentgenol.* 2006;186:144–148.

국문 초록

목적: 토끼 모델에서 림프절 전이를 진단하는 데에 있어서, 새로운 ultrasmall superparamagnetic iron oxide particle 인 PJY10 의 효능을 평가하였다.

대상 및 방법: 총 56 마리의 토끼를 대상으로, 전이림프절과 비전이림프절을 만들기 위하여, 각각 VX2 carcinoma 또는 토끼 배변으로 만든 suspension fluid 1 cc 를 MR 촬영 3 주 또는 3 일 전에 토끼의 한쪽 대퇴부 근육에 주사하였다. 모든 토끼들에 대하여, PJY10 주사 전 및 24 시간 후에 T2*-weighted 3T MR imaging 를 시행하였다 (PJY10 용량: 5.2 [n=15], 7.8 [n=17], and 10.4 [n=24] mg Fe/kg). 상기 MR 에서의 진단을 병리 진단과 비교하여, 민감도와 특이도를 계산하였다. 각각의 림프절에 대하여, Student' s t-test, Pearson correlation 와 receiver operating characteristic (ROC) curve analyses 를 사용하여 신호강도의 양적분석 - number of voxels [low] (조영증강영상에서의 normalized signal intensity 가 비조영증강영상에서의 normalized signal intensity 보다 낮은 voxel 수의 분율)과 mean signal intensity ratio (조영증강영상에서의 normalized signal intensity 대 비조영증강영상에서의 normalized signal intensity 의 비) - 을 시행하였다.

결과: 전이림프절 진단에 대한 민감도는 모든 용량에서 100%였다. 반면, 특이도는 용량이 증가함에 따라 증가하였으며, 10.4mg Fe/kg 에서 최대치 (89%)를 보였다. 비전이림프절은 전이림프절에 비하여 유의하게 더 높은 number of voxels[low] 및 더 낮은 mean signal intensity ratio 를 보였다. 전이림프절 진단에 대한 Az value 의 경우, number of voxels[low]은 0.905, mean signal intensity ratio 는 0.952 로 나타났다. 또한 전이림프절의 경우, 10.4 mg Fe/kg 용량에서, number of voxels[low] 및 mean signal intensity ratio 둘 다, 전체 림프절 면적 중에 전이된 부분이 차지하는 면적의 분율과 유의한 상관관계를 갖는 것으로 나타났다.

결론: 림프절 전이 진단에 있어 PJY10 의 최적용량은 10.4 mg Fe/kg 로 나타났으며, 상기 용량에서 전이림프절 진단에 대한 민감도와 특이도는 높았다.

주요어 : PJY10, Ultrasmall superparamagnetic iron oxide (USPIO) particle, 림프절 전이, MRI, 토끼
학 번 : 2012-21701